How is JE transmitted? JE is transmitted by the Culex mosquitoes which carries the virus from infected pigs to man What are the signs and symptoms? Those affected may present with high fever, severe headache, nausea and vomiting, and they may become confused and disorientated Is JE a serious illness? There is no specific treatment for JE. Treatment is mainly supportive. Can the mosquitoes transmit the virus from an infected person to another person?
Can a person get infected through close contact with an infected person? The virus has not been shown to be transmitted from man to man. Travel Health Information. Risk Japanese Encephalitis occurs in Southeast Asia. Symptoms The majority of cases are asymptomatic — persons do not exhibit symptoms.
Re-apply according to manufacturer's directions. Wear neutral-coloured beige, light grey clothing. If possible, wear long-sleeved, light-weight garments.
If available, pre-soak or spray outer layer clothing and gear with permethrin. Get rid of water containers around dwellings and ensure that door and window screens work properly. Apply sunscreen first followed by the repellent preferably 20 minutes later. More details on insect bite prevention. Japanese encephalitis in children in Bellary Karnataka.
Indian Pediatr. Solomon, T. Pathogenesis and clinical features of Japanese encephalitis and West Nile virus infections. Huy, B. Early mental and neurological sequelae after Japanese B encephalitis.
Tropical Med. Public Health 25 , — CAS Google Scholar. Pieper, S. Sequelae of Japanese B and mumps encephalitis. WHO Wkly. Control of Japanese encephalitis — Within Our Grasp? Upreti Shyam Raj et al. Updated estimation of the impact of a Japanese encephalitis immunization program with live, attenuated SA vaccine in Nepal. Google Scholar. Arai, S. Japanese encephalitis: surveillance and elimination effort in Japan from to Chen, P. Biologicals 3 , — Hombach, J.
Vaccine 23 , — Hoke, C. Protection against Japanese encephalitis by inactivated vaccines. Prequalification of medicines by WHO. Navigating vaccine introduction: a guide for decision-makers—Japanese encephalitis.
JE vaccines, health worker training materials. Measuring effectiveness and impact of Japanese encephalitis vaccination. Ooi, M. Clinical features, diagnosis, and management of enterovirus Lancet Neurol.
Rapid diagnosis of Japanese encephalitis by using an immunoglobulin M dot enzyme immunoassay. Cuzzubbo, A. Lewthwaite, P. Health 15 , — Khalakdina, A. Field evaluation of commercial Immunoglobulin M antibody capture ELISA diagnostic tests for the detection of Japanese encephalitis virus infection among encephalitis patients in Nepal.
Johnson, B. Hills, S. Persistence of IgM antibodies after vaccination with live attenuated Japanese encephalitis vaccine. Mulders, M.
Expansion of surveillance for vaccine-preventable diseases: building on the global polio laboratory network and the global measles and rubella laboratory network platforms. Campbell, G. Estimated global incidence of Japanese encephalitis: a systematic review.
World Health Organization 89 , — Evidence and rationale for the World Health Organization recommended standards for Japanese encephalitis surveillance. BMC Infect. Yoocharoan, P. Seroprevalence of immunity against Japanese encephalitis in Thai population. Control J. Montgomery, S. Hospital-based surveillance for Japanese encephalitis at four sites in Bangladesh, — Chaturvedi, U. Transplacental infection with Japanese encephalitis virus.
Cheng, V. Japanese encephalitis virus transmitted via blood transfusion, Hong Kong, China. Ravanini, P. Eurosurveillance 17 , 1—4 Simon-Loriere, E. Autochthonous Japanese encephalitis with yellow fever coinfection in Africa. Oliveira, A. Nett, R. Potential for the emergence of Japanese encephalitis virus in California.
Vector-Borne Zoonotic Dis. Background Paper on Japanese Encephalitis Vaccines. Zhou, B. A large-scale study on the safety and epidemiological efficacy of Japanese encephalitis JE live vaccine SA in the JE endemic areas. Chin Journal of Epidem 20 , 38—41 Biologicals 14 , — Kim, D. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine JE-CV in comparison with SA vaccine in children in the Republic of Korea.
Vaccines Immunother 10 , — Feroldi, E. Primary immunization of infants and toddlers in Thailand with Japanese encephalitis chimeric virus vaccine in comparison with SA a randomized study of immunogenicity and safety. Tsai, T. Immunogenicity of live attenuated SA Japanese encephalitis vaccine—A comparison of 1- and 3-month immunization schedules.
Victor, J. Vaccine 32 , — Wijesinghe, P. Safety and immunogenicity of live-attenuated Japanese encephalitis SA vaccine co-administered with measles vaccine in 9-month-old infants in Sri Lanka. Zaman, K. Lot-to-lot consistency of live attenuated SA Japanese encephalitis vaccine manufactured in a good manufacturing practice facility and non-inferiority with respect to an earlier product. Bista, M. Efficacy of single-dose SA vaccine against Japanese encephalitis: a case control study.
Lancet , —5 Ohrr, H. Effect of single dose of SA vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study. Lancet , —8 Tandan, J. Single dose of SA vaccine provides long-term protection against Japanese encephalitis: a case—control study in Nepalese children 5 years after immunization. Vaccine 25 , — Kumar, R. Effectiveness of one dose of SA vaccine against Japanese encephalitis.
Hennessy, S. Effectiveness of live-attenuated Japanese encephalitis vaccine SA : a case-control study. Lancet , — These measures, however, had little impact on the burden of disease. For decades, Japanese encephalitis has been a seasonal risk for Indians who live near the rice paddies, where the virus-carrying mosquitoes breed. PATH was working in partnership with the government of Andhra Pradesh to strengthen routine immunization services and introduce hepatitis B vaccines. Conversations with district- and state-level health officers, however, revealed growing concern about JE.
Investigation of encephalitis outbreaks and improved disease surveillance and diagnostics suggested a previously unrecognized high incidence of JE, prompting the government of Andhra Pradesh to act quickly. In the first year of vaccination, observed JE cases reduced by 90 percent. The working group developed a roadmap for planning JE vaccination programs.
Repeated outbreaks, combined with national awareness-raising advocacy campaigns, drove the governments of various Indian states to raise their voices and demand solutions for JE control. The GoI heard these requests. While an Indian-produced, mouse brain-derived vaccine was used to immunize children in Andhra Pradesh and other areas, the available supply fell far short of the volume needed to reach children across the entire country.
Around million children in India would need to be vaccinated, and the manufacturer of the existing mouse brain-derived vaccine could only produce less than half a million doses per year.
The vaccine also had a complicated dosing schedule and was very expensive—both challenging obstacles to vaccination programs.
CD-JEV was safe, effective, and affordable and required only one dose to achieve immunity. With a safe, available, and affordable vaccine in hand, the GoI launched a large-scale, five-year JE vaccination campaign in In just the first year, the campaigns targeted children and adolescents in 11 high-risk districts of four states and reached more than 9 million children.
0コメント